Detalhe da pesquisa
1.
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Br J Cancer
; 113(6): 872-7, 2015 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26335608
2.
Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.
Cancer Med
; 12(3): 2739-2751, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36017743
3.
Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial.
Front Oncol
; 13: 1128176, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37025596
4.
Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.
Int J Oncol
; 21(5): 1059-66, 2002 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-12370755
5.
Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin.
Mol Pharmacol
; 61(4): 742-8, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11901212
6.
Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.
Biochem Biophys Res Commun
; 295(2): 435-44, 2002 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-12150968